Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Trial Profile

NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab (MEDI4736) and Tremelimumab in Muscle-invasive Urothelial Carcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2018

At a glance

  • Drugs Cisplatin (Primary) ; Doxorubicin (Primary) ; Durvalumab (Primary) ; Methotrexate (Primary) ; Tremelimumab (Primary) ; Vinblastine (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NEMIO
  • Most Recent Events

    • 17 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 19 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
    • 28 Aug 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top